untitled
|
|
- こおが こいまる
- 7 years ago
- Views:
Transcription
1 191018
2
3 Rx =Prescription Drug NEC =New Chemical Entity GE =Generic Drug OTC =Over The Counter 3
4 04
5 5
6
7 R&D 7
8 8
9 2005 ( best in class ) MR power marketing HMG-CoA 12,963 6,223 Ca ++ 5,245 4,633 3,
10 10
11 DNAsiRNA 11
12
13 Bcr-Abl () CML (EGFR) Bcr-ABLBcrAbl 13
14
15 15
16 () () () (4.6) (65.3) (30.1) 16
17
18 Q. 18
19 Q. 19
20 Q =465 20
21 58 p 101 p 112 p 1)~3) 21
22 22
23 CMC 23
24 % 6,
25
26
27 (%) C MRSA IBS COPD (%) 17HS 27
28 POC (Phase) 28
29 AK 29
01-30
COPD 3 4 4 5 5 6 6 8 8 10 10 11 11 11 12 12 12 12 19 19 20 20 21 21 21 23 23 24 24 25 25 25 26 26 26 27 4 8 13 28 13 13 14 16 16 p10 p16 p5 p6 p23 p20 p32 p33 p33 p35 p41 p41 p37 p47 p51 p70 p54 p59 p62
More informationuntitled
CA 04 1,360 100.8 0.1 83 34,176 7.61 0.40 51,532 1.3 322,736 5.9 05 1,369 100.0 0.8 80 57,269 7.86 0.43 55,001 6.7 311,107 3.6 06 1,370 99.8 0.2 83 48,250 7.73 0.46 56,369 2.5 319,129 2.6 06/ 1-3 99.4
More information2002 715 02-13M 1. 200110 024 2. 3. 4. 100 60 5. 6. 2002715 1 1 1 4 9 9 12 12 13 14 14 15 15 17 17 18 22 22 23 25 25 25 29 200110 024 3 1 1965 500 800 3,000 2,000 1 1 60 2.84 1.173 1 2002 71 1,726 1,085
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More information- 1 -
- 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (
More informationAPO LETTER 1
No.23 2005 APRIL 7 13 15 17 17 18 18 19 20 21 1 9 APO LETTER 1 SOGO Pharmacy APO LETTER 2 APO LETTER 3 SOGO Pharmacy APO LETTER 4 APO LETTER 5 SOGO Pharmacy APO LETTER 6 Concept Message APO LETTER 7 SOGO
More information- 1 -
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - EC NEC - 27 - NEC - 28 - R NEC
More information- 16 M7.3 14 M6.5 - - - - - A-4 A-5 A-3 F-3 F-1 C-3 G-1,E-6 C-2 D-1 F-2 E-7 J-1 J-3 B-3 K-1 B-3 I-4 I-3 I-2 I-6 C-1 I-5 B-5 B-2 J-2 A-1 A-2 E-1 B-4 I-1 E-2 E-5 B-1,E-4 E-3 A-1 A-2 A-2 A-3 A-4 A-5 A-2
More information,798 14, kg ,560 10, kg ,650 2, kg ,400 19, kg ,
/ HS / TEL FAX 2007 1 18,000 9,540.00 0.53 kg 2007 1 99,000 38,518.00 0.39 kg 2007 1 30,200 11,778.00 0.39 kg 2007 1 15,000 5,565.00 0.37 kg 2007 1 21,000 7,400.00 0.35 kg 2007 1 40,000 20,579.00 0.51
More informationP.5 P.6 P.3 P.4 P.7 P.8 P.9 P.11 P.19
MOST is the best! P.5 P.6 P.3 P.4 P.7 P.8 P.9 P.11 P.19 P.14 1 2 P.14 1 2 12,036 17,025 P.14 3 P.14 4 NEW P.12P.14 5 P.12P.14 6 P.12 P.15 7 NEW P.15 8 P.15 9 P.15 7 P.15 10 P.15 10 NEW P.12 P.15 11 P.15
More informationuntitled
2011/1/22 1 vs. 2 1 2011/1/22 3 4 2 2011/1/22 5 6 3 2011/1/22 7 8 4 2011/1/22 9 H 2 N NH 2 N N S S NH 2 N O 2 S NH2 N N H S CH 3 H N N CN HN CH3 10 5 2011/1/22 11 12 6 2011/1/22 13 14 7 2011/1/22 15 16
More information2 5 6 9 19 20 23 31 32 35 39 40 41 47 48 51 52 55 1 2 1 2 3 3 4 1 2 3 4 5 5 1 2 3 6 4 5 6 7 7 8 8 1 2 3 9 4 5 6 7 8 10 9 10 11 11 1 2 3 4 12 5 6 7 8 13 1 2 14 3 4 15 1 2 3 4 16 5 17 18 19 1 2 20 1 2 3
More informationIBS - 2 -
27 3 6 14:00 16:00 3 302-1 - IBS - 2 - 1. 2. 26 3. - 3 - 4. 4-1 26 1 1 5 1 2 4 2 40 3-4 - 4-2 2 3 2 6 2 5 3 6 2 2 H25.2 2,520 H26.2 2,540 2,960 400 2 2 3 5 5 25-5 - 4-3 4 60-6 - IC 1 PR - 7 - 4 3-8 - OD
More information決算短信(連結)16.09.doc
16 9 15 9 9,584 18.9 11,823 5.5 1,005 166 67.6 16 3 29,912 450 771 846 348 39.0 ( ) 1 16 9 15 9 513 234 1.6 19.66 8.34 16 3 585 18.99 1 16 9 15 9 47,443 43,211 23,383 24,656 49.3 57.1 906.34 875.21 16
More informationMicrosoft Word - ゴールドコーストマラソン2014.docx
2014 2014 7 3 7 14:25 16:20 22:25 6:25 10:55 19:00 22:55 0:35 42.195Km 7,300km 537,844 2013 6 30 6 2 1 Dr. 1 20 10 Q1 Q1 8m 2 7 4 15 J B H..S 45 30 7 20 49 20 15 3 45 4 3 50 28 35 km 40km 4 4 6 15km 20km
More informationP.37 P.816 P.17 P.1819 contents 1 2
201211 NEW! P.37 P.816 P.17 P.1819 contents 1 2 3 4 5 6 7 8 http://www.tokiomarine-nichido.co.jp/ 1 2 16 3 11 4 1 18 9 10 5 6 11 12 18 9 10 6 7 8 13 1411 12 5 13 14 15 1615 16 21 17 18 0120-071-281 19
More informationKyoto Sangyo University Slywotzky and Morrison 1997 Slywotzky ,2001, ,550 6, ,87
1 2008 2 Slywotzky and Morrison 1997 Slywotzky 20021999 20041999,2001,2006 1999 3 3 1997 2007 10 2,550 6,674 2.6 1 2007 2,878 2 12007 2 15 658 39 20 3 13 2 OTC 8 2,294 6 6,108 3 6,911 4 10 15,900 5 9 17
More informationJAPAN MARKETING JOURNAL 110 Vol.28 No.22008
Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING
More informationJAPAN MARKETING JOURNAL 113 Vol.29 No.12009
JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 Vol.29 No.12009 JAPAN MARKETING
More informationJAPAN MARKETING JOURNAL 111 Vol.28 No.32008
Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING
More informationJpn Pharmacol Ther vol. 31 no Panos Kanavos Director, International Health Policy, Dept. of Social Policy & LSE Health, London School of Econ
Panos Kanavos Director, International Health Policy, Dept. of Social Policy & LSE Health, London School of Economics 1. Introduction ad hoc European Union: EU third party (a) (b) (c) (d) (e) value added
More information表紙23号
53 2004 2005 7 KDDI JETRO JETRO 2003 JETRO 2006 3 2005 11 2002 7 1 2 54 25 54 2001 2 HIH APRA 2002 7 150 100 APRA 5 30 20 8 Allianz Allianz 5 1 Allianz 8 Allianz Allianz 55 2004 100 7 1 2002 180 150 750
More informationNO. July 2011 Risho Now Risho Now Risho Now Risho Now Products News 179 RISHO KOGYO CO.,LTD. Chemical Science R&D Laboratory Hiroshi Okumura Products News 179 Products News 179 Products News 179
More information【修正版】加州報告書第Ⅱ部 その1.PDF
Pennsylvania, New Jersey, Maryland 1 12 10 8 6 4 2 0 John Quain Load Serving Entity Merchant Plant Load Serving Entity Over The Counter Office of Interconnection Locational Marginal Price) PECO Energy
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More informationTN3..00-43
43 42 C O O R D I N A T I O N B E T W E E N T H E F I E L D S O F R E F E R E E I N G A N D T E C H N I C A L 44 45 46 47 49 48 51 50 MEN'S MEN'S MEN'S WOMEN'S WOMEN'S WOMEN'S 53 52 55 54 NEW NEW 57 56
More informationJAPAN MARKETING JOURNAL 123 Vol.31 No.32012
Japan Marketing Academy JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN
More informationJAPAN MARKETING JOURNAL 115 Vol.29 No.32010
Japan Marketing Academy JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN
More informationJAPAN MARKETING JOURNAL 110 Vol.28 No.22008
JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110
More information西朋28
v 28 0007 0010 /WC --- The Best Photographs --- 1 28 0013 0102 --- The Best Photographs --- 2 28 0105 /ST --- The Best Photographs --- 3 28 0114 /WC 0301 /VR --- The Best Photographs --- 4 28 5 28 6 28
More information取扱説明書 [F-05E]
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
More information第1章
. 23 % 16.52 0.2 17.4 34.63 0.5 36.6 43.56 0.6 46.0 3 94.71 1.2 100 558.69 7.2 7,779.55 100 13. 24 16.1 16.0 16.8 16.6 19.6 21.1 19.4 21.1 13.2 11.5 14.4 12.5 64 57 43 2,056.7 2,056.7 2,260.7 2,204.0 113
More informationMEDIA RELEASE COMMUNIQUE AUX MEDIA MEDIENMITTEILUNG EPS
106-0031 4-16-13 MEDIA RELEASE COMMUNIQUE AUX MEDIA MEDIENMITTEILUNG 2006123 2005 2006119 14 13 10 9 10 12 0.7 29.7 10 61 1 EPS 11 2.63 42 47 10 1 1.15 2006 Galvus :LAF2372 Rasilez :SPP100 LDT600B 2005
More information,889 99, , , ,031 8,952 13,261 16,443 14,464 17,948 % ,037 8,848 10,927
2013 2013 3 3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575
More information“÷Œò›ï48
48 37 773 1 18 100 214 1 50 2 5 7 OSCE (Objective Structured Clinical Examination) 8 10 14 15 16 6 19 20 21 21 22 22 25 26 26 27 27 20 28 2 1 Over the counter 50 80 30 502 3 60 404 3 OTC OTCOver the counter
More informationⅠ.市場リスクの計測手法
1 2 3 4 { } n n 5 R R R R 1 6 7 8 9 , 10 11 12 13 14 15 T 16 T 17 18 19 20 21 22 23 99VaR 99 24 25 26 0.5 0.5 27 99 28 99 99 29 99 30 31 t-1 t-1 t-1 t-1 t-10 t-10 t-10 t-10 32 33 2 T 2 34 99 99 99 35 36
More informationCEO 2017.10.30 Agenda Agenda ) 2000 2000 10 ~ ~ GLP: Good Laboratory Practice GCP: Good Clinical Practice GMP: Good Manufacturing Practice GPSP: Good Post-marketing Study 1 10,000 Practice GLP GMP GCP
More informationuntitled
2004 8 31 () ( ) 1 30 SSY-21-ND 2006 3 2 ,,, 516403 8 5() ( 2005 ) 5,000 3 ( ) 1960 3 1970 1980 1990 XX ( ) 2000 ISO () ( ) ISO14000 2004 3 ( ) 2005 3 4 2005 9 2005 12 2005 7 2005 10 NIHON DENKEI MALAYSIA,
More informationw NEWS NEWS Y
No.472 FEB. 200315 w NEWS NEWS Y e r Y E t 1 1 y u i B 1 1 Y c fa g f o p mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr A 1 !0 1 1
More informationGT-3 P GT-3-6F GT GT GT GT GT GT GT
150-1.5GT-3 P 30-1.5GT-3-6F 40.5-1.5GT 40.50 27 45-1.5GT 45.00 30 48-1.5GT 48.00 32 51-1.5GT 51.00 34 61.5-1.5GT 61.50 41 69-1.5GT 69.00 46 70.5-1.5GT 70.50 47 72-1.5GT 72.00 48 73.5-1.5GT 73.50 49 76.5-1.5GT
More informationOLDEN D AD A AK A A K PA P D PA HYPER HYPER Y R SINTEREDPA P D A H-DPA P D A NEW
HIGH QUALITY & HIGH PERFORMANCE RMANCE MOTORCYCLE PARTS OLDEN D AD A AK A A K PA P D PA HYPER HYPER Y R SINTEREDPA P D A H-DPA P D A NEW 7 12 17 22 24 28 32 82 2 1 2 97116 5,100 79797 4,000 72454 4,200
More informationJAPAN MARKETING JOURNAL 123 Vol.31 No.32012
Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING
More informationSERIES NEW MODEL ULTIMATE POWER & LUXURY EXPERIENCE NEW NEW NEW NEW MODEL PURE RACING SPIRIT NEW NEW NEW NEW NEW NEW MODEL NEW MODEL EXTREME PERFORMANCE STD 8 8 NEW NEW MODEL NEW NEW MODEL LEISURE & LUXURY
More information山形県2012-初校.indd
2012 YAMAGATA http://www.kairyudo.co.jp/ 2 5 6 8 10 12 14 1 2 3 2 3 4 112 213 314 kg cm 20m 1500m 50m cm m 24.54 30.30 35.16 24.45 29.89 34.91 23.69 26.74 29.46 23.60 27.15 29.84 38.67 43.64 46.08 38.79
More information-1-
-1- -2 - 2000 1 1 5-3 - 21 10 2-4 - 5-5 - -6 - -7- -8 - 21 2000 21-9- IT in silico 10-10 - -11 - 20 21 1993 ICH - 12 - 2007 4 1 NIHThe National Institutes of Health2004 NIH NIH 2006 UK Clinical Research
More informationuntitled
IR 155 150 145 149 150 151 150 147 143 148 145 % 15.0 10 140 135 133 10.0 130 125 17 23 27 32 37 42 47 52 57 5.0 0.0 15 13.1% 15 13.2% 1564 70.0% 1564 63.8% 65 16.8% 65 21.2% 5.0 0% 20% 40% 60% 80% 100%
More information......1201-P1.`5
2009. No356 2/ 5 6 a b b 7 d d 6 ca b dd a c b b d d c c a c b - a b G A bb - c a - d b c b c c d b F F G & 7 B C C E D B C F C B E B a ca b b c c d d c c d b c c d b c c d b d d d d - d d d b b c c b
More informationW810 QX100 QX30 QX10 W810 QX100 QX30 QX10 RX100 RX100 WX500 WX350 RX100 RX100 HX400V HX90V HX60V RX100 RX100 RX100 RX100 HX400V HX90V HX60V WX500 WX350 RX100 RX100 WX500 WX350 RX100 RX100 HX400V HX90V
More informationNo.19
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
More information